Matinas Biopharma Holdings Current Ratio 2012-2020 | MTNB

Matinas Biopharma Holdings current ratio from 2012 to 2020. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Matinas Biopharma Holdings Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2020-03-31 $0.07B $0.00B 29.10
2019-12-31 $0.03B $0.00B 9.66
2019-09-30 $0.03B $0.00B 13.06
2019-06-30 $0.04B $0.00B 10.81
2019-03-31 $0.04B $0.00B 12.81
2018-12-31 $0.01B $0.00B 4.61
2018-09-30 $0.01B $0.00B 2.85
2018-06-30 $0.01B $0.00B 6.27
2018-03-31 $0.01B $0.00B 4.75
2017-12-31 $0.01B $0.00B 4.50
2017-09-30 $0.01B $0.00B 5.40
2017-06-30 $0.01B $0.00B 8.79
2017-03-31 $0.02B $0.00B 8.60
2016-12-31 $0.01B $0.00B 3.16
2016-09-30 $0.01B $0.00B 4.80
2016-06-30 $0.00B $0.00B 0.58
2016-03-31 $0.00B $0.00B 1.45
2015-12-31 $0.00B $0.00B 3.15
2015-09-30 $0.01B $0.00B 5.60
2015-06-30 $0.01B $0.00B 6.06
2015-03-31 $0.01B $0.00B 3.70
2014-12-31 $0.00B $0.00B 2.51
2014-09-30 $0.01B $0.00B 5.01
2014-06-30 $0.01B $0.00B 7.67
2014-03-31 $0.01B $0.00B 12.84
2013-12-31 $0.01B $0.00B 12.72
2013-09-30 $0.01B $0.00B 25.09
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
2011-12-31 $0.00B $0.00B 1.33
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.170B $0.000B
Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company's lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $66.739B 37.88
Takeda Pharmaceutical (TAK) Japan $58.011B 10.17
Astellas Pharma (ALPMY) Japan $32.072B 16.02
Eisai (ESALY) Japan $23.340B 43.48
UCB SA (UCBJF) Belgium $19.723B 0.00
Merck (MKGAF) Germany $14.934B 19.58
Grifols, S.A (GRFS) Spain $13.579B 16.88
Catalent (CTLT) United States $11.913B 46.05
Neurocrine Biosciences (NBIX) United States $11.154B 51.55
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $9.945B 0.00
Ono Pharmaceutical (OPHLF) Japan $9.254B 19.78
Ionis Pharmaceuticals (IONS) United States $7.782B 41.38
Orion OYJ (ORINY) Finland $7.289B 32.66
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $7.270B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.744B 10.80
IPSEN SA ADR (IPSEY) France $6.676B 0.00
United Therapeutics (UTHR) United States $5.388B 10.21
STADA ARZNEIMI (STDAF) Germany $4.916B 0.00
Hypermarcas (HYPMY) Brazil $4.192B 12.75
Evotec AG (EVTCY) Germany $4.119B 66.40
Nektar Therapeutics (NKTR) United States $4.112B 0.00
ChemoCentryx (CCXI) United States $3.711B 0.00
Arrowhead Pharmaceuticals (ARWR) United States $3.303B 360.56
PTC Therapeutics (PTCT) United States $3.008B 0.00
FibroGen (FGEN) United States $2.913B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.603B 10.70
Cronos Group (CRON) Canada $2.334B 66.90
Pacira BioSciences (PCRX) United States $1.976B 40.45
Sage Therapeutics (SAGE) United States $1.826B 0.00
USANA Health Sciences (USNA) United States $1.794B 18.40
Xencor (XNCR) United States $1.702B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.699B 0.00
Heron Therapeutics (HRTX) United States $1.671B 0.00
Theravance Biopharma (TBPH) Cayman Islands $1.659B 0.00
Zogenix (ZGNX) United States $1.629B 0.00
Corcept Therapeutics (CORT) United States $1.618B 16.05
Akebia Therapeutics (AKBA) United States $1.587B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.560B 11.94
Portola Pharmaceuticals (PTLA) United States $1.406B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.398B 15.06
Karyopharm Therapeutics (KPTI) United States $1.302B 0.00
Tilray (TLRY) Canada $1.260B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.224B 0.00
Esperion Therapeutics (ESPR) United States $1.200B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.002B 44.71
Translate Bio (TBIO) United States $0.984B 0.00
Endo (ENDP) Ireland $0.914B 1.42
ImmunoGen (IMGN) United States $0.801B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.769B 0.00
Aerie Pharmaceuticals (AERI) United States $0.684B 0.00
Molecular Templates (MTEM) United States $0.684B 0.00
Collegium Pharmaceutical (COLL) United States $0.681B 0.00
Indivior (INVVY) United States $0.640B 7.94
Ardelyx (ARDX) United States $0.616B 0.00
Trillium Therapeutics (TRIL) Canada $0.613B 0.00
Radius Health (RDUS) United States $0.568B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.508B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.499B 0.00
Innate Pharma SA (IPHYF) France $0.489B 0.00
Siga Technologies (SIGA) United States $0.485B 0.00
Flexion Therapeutics (FLXN) United States $0.458B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.448B 10.82
DURECT (DRRX) United States $0.445B 0.00
Organogenesis Holdings (ORGO) United States $0.435B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.433B 16.91
Harpoon Therapeutics (HARP) United States $0.433B 0.00
MEI Pharma (MEIP) United States $0.410B 0.00
Ocular Therapeutix (OCUL) United States $0.377B 0.00
Calithera Biosciences (CALA) United States $0.368B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.346B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.319B 0.00
TherapeuticsMD (TXMD) United States $0.304B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.302B 0.00
Lannett Co Inc (LCI) United States $0.299B 6.55
Oasmia Pharmaceutical AB (OASMY) Sweden $0.279B 0.00
Concert Pharmaceuticals (CNCE) United States $0.267B 0.00
CASI Pharmaceuticals (CASI) United States $0.264B 0.00
Redhill Biopharma (RDHL) Israel $0.244B 0.00
OptiNose (OPTN) United States $0.243B 0.00
Rafael Holdings (RFL) United States $0.236B 0.00
KalVista Pharmaceuticals (KALV) United States $0.209B 0.00
PROFOUND MEDICL (PROF) Canada $0.202B 0.00
Jounce Therapeutics (JNCE) United States $0.196B 4.68
VAXART, INC (VXRT) United States $0.194B 0.00
Nature's Sunshine Products (NATR) United States $0.193B 25.39
Taiwan Liposome (TLC) Taiwan $0.185B 0.00
Xeris Pharmaceuticals (XERS) United States $0.176B 0.00
IMV INC (IMV) Canada $0.176B 0.00
Aquestive Therapeutics (AQST) United States $0.173B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.137B 0.00
Altimmune (ALT) United States $0.117B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.117B 0.00
Recro Pharma (REPH) United States $0.110B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.107B 0.00
Champions Oncology (CSBR) United States $0.106B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.103B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.102B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.091B 0.00
Otonomy (OTIC) United States $0.091B 0.00
Sundial Growers (SNDL) Canada $0.087B 0.00
SCYNEXIS (SCYX) United States $0.087B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.081B 0.00
CTI BioPharma (CTIC) United States $0.081B 0.00
CV Sciences (CVSI) United States $0.078B 0.00
Hemispherx BioPharma (AIM) United States $0.078B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.076B 0.00
Onconova Therapeutics (ONTX) United States $0.076B 0.00
Heat Biologics (HTBX) United States $0.075B 0.00
Nivalis Therapeutics (ALPN) United States $0.072B 0.00
Aclaris Therapeutics (ACRS) United States $0.059B 0.00
MediWound (MDWD) Israel $0.056B 0.00
RENEURON GP (RNUGF) United Kingdom $0.056B 0.00
Biomerica (BMRA) United States $0.054B 0.00
Infinity Pharmaceuticals (INFI) United States $0.052B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.051B 30.36
Opiant Pharmaceuticals (OPNT) United States $0.050B 105.82
Natural Alternatives (NAII) United States $0.049B 0.00
IsoRay (ISR) United States $0.048B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.045B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.045B 0.00
GTx (ONCT) United States $0.045B 0.00
Lipocine (LPCN) United States $0.043B 0.00
PolarityTE (PTE) United States $0.043B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.040B 0.00
Forward Pharma (FWP) Denmark $0.040B 0.00
Addex Therapeutics (ADXN) Switzerland $0.040B 0.00
Mannatechorporated (MTEX) United States $0.039B 7.37
Neos Therapeutics (NEOS) United States $0.038B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.038B 0.00
Novan (NOVN) United States $0.036B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.036B 0.00
ElectroCore (ECOR) United States $0.035B 0.00
AgeX Therapeutics (AGE) United States $0.034B 0.00
Jaguar Animal Health (JAGX) United States $0.026B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.024B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.023B 0.00
India Globalization Capital (IGC) United States $0.022B 0.00
Iterum Therapeutics (ITRM) Ireland $0.021B 0.00
Bio-Path Holdings (BPTH) United States $0.020B 0.00
Regulus Therapeutics (RGLS) United States $0.018B 0.00
ProPhase Labs (PRPH) United States $0.018B 0.00
Can-Fite Biopharma (CANF) Israel $0.017B 0.00
Flex Pharma (SLRX) United States $0.017B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.015B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.014B 0.00
Cyanotech (CYAN) United States $0.013B 0.00
Shineco (TYHT) China $0.013B 0.00
China SXT Pharmaceuticals (SXTC) China $0.011B 0.00
RXi Pharmaceuticals (PHIO) United States $0.011B 0.00
Vical (BBI) United States $0.011B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.007B 0.00
Midatech Pharma (MTP) United Kingdom $0.007B 0.00
HANCOCK JAFFE (HJLI) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
CannTrust Holdings (CTST) Canada $0.000B 0.00